Lupus & antiphospholipid syndrome
Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update
Authors' conclusion
There has been no validation of previously identified prognostic factors to guide outcome in anti-CD20 treated lupus patients. Hypothesis-driven studies of several novel markers however, demonstrate prognostic value
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with anti-CD20 monoclonal antibodies (MAb) (rituximab studies published prior to 2015 excluded)17 + 8 studies included
- Outcome
- Predictive and prognostic factors of clinical response following anti-CD20 therapy
Methodological detailsnarrative synthesis, RoB2 and QUIPS risk of bias assessment
- Narrative synthesis
- RoB2 and QUIPS risk of bias assessment
Pooled result
As reported in the abstract
- Included studies: two post-hoc analyses of rituximab randomized controlled trials (RCTs), one RCT of ocrelizumab, one of obinutuzumab, 16 cohort studies of rituximab
- Overall quality of evidence (QoE) low or very low
- Wide heterogeneity in definitions of disease activity and outcome measures, non-standardized laboratory cut-offs, failure to account for confounders, multiple subgroup analyses
- B cell depletion and novel biomarkers (S100 proteins, FCGR genotype, anti-vimentin and anti-drug antibodies) showed some evidence of prognostic value; QoE limited by moderate to high risk of bias, early phase of investigation and imprecision
Original publication
Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update. Semin Arthritis Rheum. Published 16 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →